Target intelligence / Profile preview

Neuronal nitric oxide synthase (nNOS)

Target
nNOS
Molecular classification
Enzyme, Oxidoreductase, Nitric oxide synthase family
01

Overview

Neuronal nitric oxide synthase (nNOS, NOS1) is a constitutively expressed enzyme predominantly found in neurons of the central and peripheral nervous system, as well as in other tissues such as skeletal muscle and epithelial cells. It catalyzes the production of nitric oxide (NO) from L-arginine, a process requiring cofactors such as calmodulin, heme, tetrahydrobiopterin, FAD, FMN, and NADPH. The enzymatic activity depends on dimerization and specific protein–protein interactions mediated by its PDZ domain. nNOS-derived NO is critical in long-term synaptic plasticity, neurogenesis, central cardiovascular regulation, and smooth muscle relaxations. Dysfunction or aberrant regulation of nNOS is implicated in multiple diseases, including neurodegeneration, cardiovascular pathology, and some psychiatric conditions. Clarification: The term "binding domain restoration" is atypical and seems to allude to therapeutic strategies aimed at restoring nNOS interactions—such as its PDZ domain-mediated localization or functional protein–protein interplay (e.g., with PSD-95, caveolin) rather than a recognized molecular entity or target. The correct target, in context, is "Neuronal nitric oxide synthase."

Other names
NOS1neuronal NOS
02

Mechanism of action

Inhibition of NO synthesis via competitive inhibition at the L-arginine binding site Interference with calmodulin binding Disruption of dimerization or heme binding

03

Biological functions

Signal transductionRegulation of synaptic transmissionNeurogenesisCentral regulation of blood pressureRegulation of smooth muscle tone
04

Disease associations

Neurodegenerative diseaseCardiovascular diseasePsychiatric disordersAtherosclerosis
05

Safety considerations

Potential systemic hypertensionImpairment of learning and memoryInterference with normal vascular and neuronal function
06

Interacting drugs

Selective and non-selective nitric oxide synthase inhibitors (e.g., 7-nitroindazole, L-NAME)
07

Biomarkers

nNOS protein expression in tissuesNitric oxide (NO) metabolites (nitrate/nitrite) levelsPossibly S-nitrosylation patterns

Beyond the preview

Go deeper on Neuronal nitric oxide synthase (nNOS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuronal nitric oxide synthase (nNOS).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call